Perrigo wins US FDA tentative approval for generic Soolantra Cream, 1%
31 January 2018 -

Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) reported on Tuesday the receipt of the tentative approval from the US Food and Drug Administration for the generic version of Soolantra (ivermectin) cream, 1% for the treatment of inflammatory lesions of rosacea.

According to IMS Health, the annual market sales for Soolantra Cream, 1% for the last 12 months were approximately USD120m, added the company.

The company's EVP and president John Wesolowski stated the approval is Rx team's fifth generic product approval this month.

Perrigo added that it previously reported a patent litigation suit with Galderma Laboratories LP, Galderma SA and Nestle Skin Health SA for Soolantra Cream, 1%.